2Morris MJ, Scher HI. Novel strategies and therapeutics for the treatment of prostate careinoma[J ]. Cancer, 2000, 89(6): 1329 -1348.
3Sheu JR, Yen MH, Kan YC, et al. Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha (v) beta3 integrin monoclonal antibody [ J ]. Biochim Biophys Acta,1997, 1336(3) :445 - 454.
4Wojtowicz Praga S, Low J, Marshall J, et al. Phase I trial of a novel matrix metallopreteinase inhibitor batimastat (BB-94)in patients with advanced cancer[J]. Invest New Drugs, 1996, 14(2): 193 - 202.
5Steward WP. Marimastat(BB2516): current status of development[J]. Cancer Chemother Pharmacol, 1999, 43(Suppl): S56 -S60.
6Tiemey GM, Griffith NR, Stuart RC, et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer[J]. Eur J Cancer, 1999, 35(4) :563 -568.
7Chamichael J, Ledermann J, Woll PJ, et al. Phase I study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer[J]. Porc Am Soc Clin Oncol, 1998,17: 232a.
8Zhang Y, Griffith EC, Sage J, et al. Cell cycle inhibition by the antiangiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1[J]. Proc Nail Acad Sci USA, 2000, 97(12):6427 - 6432.
9Minischetti M, Vacca A, Ribatti D, et al. TNP-470 and recombinant human interferon-alpha2a inhibits angiogenesis synergistically[ J ]. Br J Heematol, 2000,109(4) :829 - 837.
10Verheul HM, Panigraphy D, Yuan J, et al. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumor growth in rabbits[J]. Br J Cancer, 1999, 79(1): 114 - 118.
